Pashna Munshi, MD, provides an overview of adverse event data from the REACH3 trial of ruxolitinib in patients with steroid-refractory cGVHD and discusses management of patients’ side effects in clinical practice.
Case: A 58-Year-Old Man With Moderate Steroid-Refractory Chronic Graft-Versus-Host Disease
Initial Presentation
First-line Treatment
Second-line Treatment